Should a patient who has been taking low‑dose aspirin (81 mg) daily for 15 years without any gastrointestinal bleeding continue the medication?

Should Low-Dose Aspirin Be Continued After 15 Years Without Bleeding?

Yes, continue the aspirin indefinitely if it was initiated for secondary prevention (history of MI, stroke, PCI, or established cardiovascular disease), but strongly consider discontinuation if it was started solely for primary prevention, especially given the patient's 15-year exposure without documented cardiovascular events. 1, 2, 3

Critical Decision Point: Primary vs. Secondary Prevention

The answer hinges entirely on why aspirin was started 15 years ago:

If Started for Secondary Prevention (History of CVD Events)

• Continue aspirin indefinitely 1, 4, 5
• After PCI, coronary stenting, MI, stroke, or established cardiovascular disease, aspirin should be continued for life 1
• The 81 mg daily dose is preferred over higher maintenance doses to minimize bleeding risk while maintaining efficacy 1, 4
• The absence of bleeding over 15 years is reassuring but does not justify discontinuation when aspirin is indicated for secondary prevention

If Started for Primary Prevention (No Prior CVD Events)

• Strongly consider discontinuation based on current evidence 2, 3
• The 2019 ACC/AHA Primary Prevention Guidelines and 2022 USPSTF recommendations represent a major shift away from routine aspirin for primary prevention 2, 3
• For adults ≥60 years, aspirin for primary prevention is now a Class III: Harm recommendation (should NOT be used) 2
• For adults 40-59 years with ≥10% 10-year ASCVD risk, aspirin is only a Class IIb recommendation (may be considered in select individuals) 2

The Evidence Evolution

Recent high-quality trials have fundamentally changed aspirin's risk-benefit profile for primary prevention:

• The 2022 USPSTF systematic review of over 118,000 patients showed that bleeding risks now generally outweigh cardiovascular benefits in primary prevention, particularly with contemporary use of statins and antihypertensives 3, 6
• Meta-analyses demonstrate aspirin increases major bleeding by 42% (RR 1.42), intracranial hemorrhage by 33% (RR 1.33), and GI bleeding by 91% (RR 1.91) 6
• The cardiovascular benefit (11% reduction in MACE) is modest and increasingly questioned in the era of modern preventive therapies 6

Bleeding Risk Assessment

Even without prior bleeding, cumulative risk increases with:

• Age ≥60 years (particularly ≥70 years) 2, 3
• Duration of use (bleeding risk persists throughout treatment) 7
• Concomitant medications: NSAIDs (8.6-fold increase), steroids (10.5-fold), SSRIs (11.7-fold), or anticoagulants 7, 8
• History of peptic ulcer disease, even if remote 9, 10
• Uncontrolled hypertension 11

The fact that 15 years have passed without bleeding does NOT eliminate future risk—bleeding events can occur at any time during aspirin therapy 7.

Specific Clinical Algorithm

Step 1: Determine the original indication

• Review records for history of MI, stroke, PCI, peripheral vascular disease, or angina
• If documented cardiovascular disease → Continue aspirin 1, 12
• If no documented cardiovascular disease → Proceed to Step 2

Step 2: Calculate current 10-year ASCVD risk

• If age ≥60 years → Discontinue aspirin (Class III: Harm for primary prevention) 2
• If age 40-59 years with <10% 10-year risk → Discontinue aspirin 2
• If age 40-59 years with ≥10% risk → Proceed to Step 3

Step 3: Assess bleeding risk factors

• If any increased bleeding risk (see list above) → Discontinue aspirin (Class III: Harm) 2
• If no bleeding risk factors AND patient strongly prefers continuation → May continue with shared decision-making 2

Special Considerations for Diabetes

If the patient has diabetes (a common reason for historical aspirin use):

• The 2004 ADA guidelines recommended aspirin for primary prevention in diabetics over 40 9
• This recommendation is now outdated and superseded by current guidelines that do not support routine aspirin in diabetic patients without established CVD 2
• Recent evidence shows increased GI symptoms/bleeding in diabetic patients on aspirin, particularly within the first 3 years but persisting long-term 13

Common Pitfall to Avoid

Do not assume that 15 years without bleeding means the patient can safely continue aspirin indefinitely. The absence of past bleeding does not predict future safety, and bleeding risk accumulates over time. The critical error is continuing aspirin for primary prevention simply because "it's been working fine"—the question is whether it was ever appropriately indicated and whether current evidence supports continuation 2, 3.

Practical Implementation

If discontinuing aspirin:

• No tapering required—aspirin can be stopped abruptly 2
• Ensure optimal management of other cardiovascular risk factors (statin therapy, blood pressure control, smoking cessation) 2
• Document the reason for discontinuation clearly in the medical record

If continuing aspirin for secondary prevention:

• Maintain 81 mg daily dose 1, 4
• Consider enteric-coated formulation if any GI symptoms 13
• Avoid concomitant NSAIDs when possible 7, 8
• Consider PPI co-therapy if high GI bleeding risk 14, 15